In the past 25 years — from 2000 to 2024 — we have witnessed a revolution in the management, treatment, and outcome of what used to be the most lethal hematologic cancer: Philadelphia ...

Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- ...

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve ...

BUFFALO, N.Y. — A 6-year-old who was diagnosed with a rare form of leukemia is in remission and ready for first grade after receiving an innovative cancer treatment at Roswell Park Comprehensive Care ...

Decitabine/cedazuridine plus venetoclax met its primary endpoint with a complete response rate of 46.5%. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA ...